Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

NCT05263609 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI left University

Conditions

Renal Cell Cancer

Interventions

DRUG: Axitinib
DRUG: Pembrolizumab

Sponsor

University of Oklahoma

Collaborators

[object Object]
[object Object]